JNJ - Johnson & Johnson

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson'.

Aug 31, 2026 01:08 PM • businesswire.com

JEPI's Monthly Payouts Shrunk as the Bull Market Raged. Here's When That Changes

JEPI's monthly payouts have quietly shrunk all year while the broader market surged past it, and the one event that could reverse both trends is now closer than most investors expect.

Aug 31, 2026 11:33 AM • 247wallst.com

This Popular Healthcare ETF Is Diluting Your Dividend Income

XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.

Aug 31, 2026 10:02 AM • 247wallst.com

Two Recessions Couldn't Stop These 4 Healthcare Stocks From Raising Dividends

Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns.

Aug 31, 2026 07:58 AM • 247wallst.com

These 3 Dividend Stocks Have Survived Every Recession Since 1970. Retirees Trust Them for a Reason.

Retirees rarely want excitement from an income holding. They want a check that arrives, gets bigger, and does not care what the economy is doing.

Aug 31, 2026 07:53 AM • 247wallst.com

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.

J&J's portfolio primarily includes small biotech and medtech companies. Its largest investment is in the company in its portfolio with the largest market cap.

Aug 31, 2026 12:44 AM • fool.com

How a 79-Year-Old Widow Built a $6,100 Monthly Paycheck Around O, JNJ, and PFF

Converting a nest egg into a reliable monthly paycheck sounds straightforward until you realize the yield tier you choose can demand nearly three times as much capital for the same income target. A 79-year-old widow with fixed expenses and no room for error found a middle path most retirees overlook entirely.

Aug 30, 2026 05:36 AM • 247wallst.com

Deutsche Bank AG Has $3.98 Billion Stake in Johnson & Johnson $JNJ

Deutsche Bank AG raised its position in shares of Johnson and Johnson (NYSE: JNJ) by 8.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,661,323 shares of the company's stock after acquiring an additional 1,225,676 shares during the quarter. Johnson and Johnson

Aug 30, 2026 12:14 AM • defenseworld.net

Commerzbank Aktiengesellschaft FI Raises Stock Position in Johnson & Johnson $JNJ

Commerzbank Aktiengesellschaft FI boosted its position in shares of Johnson and Johnson (NYSE: JNJ) by 5.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 630,281 shares of the company's stock after buying an additional 34,975 shares during the quarter. Johnson and Johnson

Aug 30, 2026 12:14 AM • defenseworld.net

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie continues to expand its portfolio in high-growth areas like immunology and neuroscience. Johnson & Johnson maintains a massive footprint across both medicines and medical technology.

Aug 29, 2026 09:21 AM • fool.com

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Aug 28, 2026 08:46 AM • zacks.com

Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.

Johnson and Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.

Aug 28, 2026 06:00 AM • fool.com

Cashing Out a Pension or Taking the Monthly Check? The Dividend Answer for a $610,000 Lump Sum

A $610,000 pension lump sum sounds like freedom, but the monthly check comes with a guarantee that a dividend portfolio simply cannot replicate. Before you sign anything, there are three numbers that expose which choice actually leaves you better off.

Aug 28, 2026 05:41 AM • 247wallst.com

What a $1.55 Million Portfolio Actually Pays After Taxes, Medicare Premiums, and Reality

A seven-figure portfolio looks like security until federal taxes, Medicare surcharges, Social Security phase-ins, and inflation each take their share. What actually clears into your checking account from $1.55 million depends on decisions most retirees never see coming.

Aug 28, 2026 04:43 AM • 247wallst.com

Bitcoin Powers Gains as Permanent Portfolio ETF Approaches $25M

Bitcoin exposure has powered early gains in the Porter & Company Porter Portfolio Index ETF (PCPP). The fund has grown to $23.9 million in assets less than three months after its launch, according to ETF Database data.

Aug 27, 2026 11:35 AM • etftrends.com

This $1.75 Million Portfolio Pays $10,200 a Month From Three Income Buckets

Chasing a 7% blended yield across a $1.75 million portfolio sounds straightforward until you realize that loading up on the highest payers quietly destroys the very income stream you built. Three buckets solve the problem in ways that a single fund simply cannot.

Aug 27, 2026 10:38 AM • 247wallst.com

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.

Aug 27, 2026 07:51 AM • zacks.com

China approves J&J's oral psoriasis pill, says drugmaker

China's ​drug regulator has approved Johnson & Johnson's oral ‌pill for psoriasis, the company said on Thursday, intensifying competition in the world's second-largest pharmaceutical market ​with rivals including Bristol Myers Squibb and ​AbbVie.

Aug 27, 2026 01:42 AM • reuters.com

Johnson & Johnson Just Got a Big FDA Win

Imaavy can be used to treat patients aged 12 and older with warm autoimmune hemolytic anemia (wAIHA), a rare blood disease. It's the second FDA win for JNJ in as many months.

Aug 26, 2026 09:30 PM • fool.com

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $270.27, denoting a -1.05% move from the preceding trading day.

Aug 26, 2026 02:46 PM • zacks.com

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

$287.00 (was $257.59)

Guggenheim

Aug 06, 2026 06:41 AM • TheFly

Johnson & Johnson (JNJ) PT Raised to $280 at Raymond JamesMember Login

$280.00 (was $254.45)

Raymond James

Aug 03, 2026 02:37 PM • StreetInsider

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

$282.00 (was $256.35)

Wells Fargo

Aug 03, 2026 06:58 AM • TheFly

Johnson & Johnson price target raised to $300 from $290 at Argus

$300.00 (was $266.13)

David Toung · Argus Research

Jul 29, 2026 09:26 AM • TheFly

Johnson & Johnson upgraded to Buy at Freedom Broker after strong quarter

$280.00 (was $249.75)

Ilya Zubkov · Johnson Rice

Jul 16, 2026 01:26 PM • TheFly

Johnson & Johnson price target raised to $305 from $265 at Scotiabank

$305.00 (was $248.94)

Scotiabank

Jul 16, 2026 10:11 AM • TheFly

Johnson & Johnson price target raised to $265 from $258 at Raymond James

$265.00 (was $250.50)

Raymond James

Jul 16, 2026 08:49 AM • TheFly

Johnson & Johnson (JNJ) PT Raised to $261 at Bernstein SocGenMember Login

$261.00 (was $250.49)

Johnson Rice

Jul 16, 2026 08:46 AM • StreetInsider

Johnson & Johnson price target raised to $282 from $275 at Goldman Sachs

$282.00 (was $247.02)

Goldman Sachs

Jul 16, 2026 07:49 AM • TheFly

Johnson & Johnson price target raised to $294 from $284 at Morgan Stanley

$294.00 (was $247.02)

Terence Flynn · Morgan Stanley

Jul 16, 2026 06:49 AM • TheFly

Johnson & Johnson price target raised to $272 from $263 at Wells Fargo

$272.00 (was $247.02)

Wells Fargo

Jul 16, 2026 06:14 AM • TheFly

Johnson & Johnson price target raised to $260 from $250 at Stifel

$260.00 (was $247.02)

Rick Wise · Stifel Nicolaus

Jul 15, 2026 03:28 PM • TheFly

Johnson & Johnson price target raised to $287 from $265 at RBC Capital

$287.00 (was $257.61)

RBC Capital

Jul 13, 2026 09:14 AM • TheFly

Johnson & Johnson price target raised to $284 from $283 at Morgan Stanley

$284.00 (was $267.24)

Terence Flynn · Morgan Stanley

Jul 08, 2026 07:38 AM • TheFly

Johnson & Johnson price target raised to $290 from $280 at HSBC

$290.00 (was $258.65)

HSBC

Jul 06, 2026 10:23 AM • TheFly

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

$270.00 (was $253.56)

Vamil Divan · Guggenheim

Jun 26, 2026 08:30 AM • TheFly

Johnson & Johnson (JNJ) PT Raised to $270 at GuggenheimMember Login

$270.00 (was $253.29)

Johnson Rice

Jun 26, 2026 07:38 AM • StreetInsider

Johnson & Johnson upgraded to Outperform from Market Perform at Leerink

$265.00 (was $224.26)

David Risinger · Leerink Partners

May 13, 2026 06:04 AM • TheFly

Johnson & Johnson price target raised to $266 from $244 at Guggenheim

$266.00 (was $232.71)

Guggenheim

Apr 20, 2026 08:24 AM • TheFly

Johnson & Johnson price target raised to $283 from $267 at Morgan Stanley

$283.00 (was $239.66)

Morgan Stanley

Apr 15, 2026 08:31 AM • TheFly